Join us at Health Research Day — June 6th at Canton Waterfront Park, Baltimore! Learn More →

Recruiting NCT04853251

A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)

Conditions: Neovascular Age-related Macular Degeneration

Sex: All

Ages: 50 Years – N/A

Healthy volunteers: No

Phase: PHASE4

Enrollment: 188

Sponsor: Genentech, Inc.

Location: Barnet Dulaney Perkins Eye Center Mesa Arizona

This study will assess corneal endothelial cells in participants with nAMD treated with PDS refilled every 24 weeks (Q24W).

Inclusion Criteria Ocular Inclusion Criteria: * Diagnosis of nAMD prior to screening as determined by the investigator * Difference of \

Interested in this study? View the official listing for contact and enrollment details.

Source: ClinicalTrials.gov (NCT04853251). StuddyBuddy aggregates publicly available trial information.